Literature DB >> 33374773

Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor β (PDGFRβ) Imaging: Influence of Different Linkers.

Nurmaya Effendi1,2, Kenji Mishiro1, Kazuhiro Shiba3, Seigo Kinuya4, Kazuma Ogawa1,5.   

Abstract

The purpose of this study is to develop peptide-based platelet-derived growth factor receptor β (PDGFRβ) imaging probes and examine the effects of several linkers, namely un-natural amino acids (D-alanine and β-alanine) and ethylene-glycol (EG), on the properties of Ga-DOTA-(linker)-IPLPPPRRPFFK peptides. Seven radiotracers, 67Ga-DOTA-(linker)-IPLPPPRRPFFK peptides, were designed, synthesized, and evaluated. The stability and cell uptake in PDGFRβ positive peptide cells were evaluated in vitro. The biodistribution of [67Ga]Ga-DOTA-EG2-IPLPPPRRPFFK ([67Ga]27) and [67Ga]Ga-DOTA-EG4-IPLPPPRRPFFK ([67Ga]28), which were selected based on in vitro stability in murine plasma and cell uptake rates, were determined in BxPC3-luc-bearing nu/nu mice. Seven 67Ga-labeled peptides were successfully synthesized with high radiochemical yields (>85%) and purities (>99%). All evaluated radiotracers were stable in PBS (pH 7.4) at 37 °C. However, only [67Ga]27 and [67Ga]28 remained more than 75% after incubation in murine plasma at 37 °C for 1 h. [67Ga]27 exhibited the highest BxPC3-luc cell uptake among the prepared radiolabeled peptides. As regards the results of the biodistribution experiments, the tumor-to-blood ratios of [67Ga]27 and [67Ga]28 at 1 h post-injection were 2.61 ± 0.75 and 2.05 ± 0.77, respectively. Co-injection of [67Ga]27 and an excess amount of IPLPPPRRPFFK peptide as a blocking agent can significantly decrease this ratio. However, tumor accumulation was not considered sufficient. Therefore, further probe modification is required to assess tumor accumulation for in vivo imaging.

Entities:  

Keywords:  PDGFRβ; imaging; peptide

Mesh:

Substances:

Year:  2020        PMID: 33374773      PMCID: PMC7795354          DOI: 10.3390/molecules26010041

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  48 in total

1.  Influencing receptor-ligand binding mechanisms with multivalent ligand architecture.

Authors:  Jason E Gestwicki; Christopher W Cairo; Laura E Strong; Karolyn A Oetjen; Laura L Kiessling
Journal:  J Am Chem Soc       Date:  2002-12-18       Impact factor: 15.419

2.  PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.

Authors:  Vaishali Kapoor; Abhay Kumar Singh; Buck E Rogers; Dinesh Thotala; Dennis E Hallahan
Journal:  J Control Release       Date:  2019-02-11       Impact factor: 9.776

3.  Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity.

Authors:  S Maudsley; A M Zamah; N Rahman; J T Blitzer; L M Luttrell; R J Lefkowitz; R A Hall
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

4.  Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53.

Authors:  Jiuhong Yu; Xu-Wen Liu; Hyeong-Reh Choi Kim
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

Review 5.  PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

Authors:  Arne Ostman
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

6.  Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.

Authors:  Yinnong Jia; Wen Shi; Zhengyuan Zhou; Nilesh K Wagh; Wei Fan; Susan K Brusnahan; Jered C Garrison
Journal:  Nucl Med Biol       Date:  2015-07-29       Impact factor: 2.408

7.  Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.

Authors:  Joanna Strand; Zohreh Varasteh; Olof Eriksson; Lars Abrahmsen; Anna Orlova; Vladimir Tolmachev
Journal:  Mol Pharm       Date:  2014-07-23       Impact factor: 4.939

Review 8.  PDGF receptors as targets in tumor treatment.

Authors:  Arne Ostman; Carl-Henrik Heldin
Journal:  Adv Cancer Res       Date:  2007       Impact factor: 6.242

9.  Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.

Authors:  Kazuma Ogawa; Atsushi Ishizaki; Kenichiro Takai; Yoji Kitamura; Tatsuto Kiwada; Kazuhiro Shiba; Akira Odani
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

10.  Peptide-based targeting of the platelet-derived growth factor receptor beta.

Authors:  Vasileios Askoxylakis; Annabell Marr; Annette Altmann; Annette Markert; Walter Mier; Jürgen Debus; Peter E Huber; Uwe Haberkorn
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

View more
  3 in total

1.  Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics.

Authors:  Kenji Mishiro; Mengfei Wang; Saki Hirata; Takeshi Fuchigami; Kazuhiro Shiba; Seigo Kinuya; Kazuma Ogawa
Journal:  RSC Med Chem       Date:  2022-06-30

2.  Synthesis and evaluation of radiogallium-labeled long-chain fatty acid derivatives as myocardial metabolic imaging agents.

Authors:  Nurmaya Effendi; Kenji Mishiro; Hiroshi Wakabayashi; Malwina Gabryel-Skrodzka; Kazuhiro Shiba; Junichi Taki; Renata Jastrząb; Seigo Kinuya; Kazuma Ogawa
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

3.  Synthesis and Characterization of Radiogallium-Labeled Cationic Amphiphilic Peptides as Tumor Imaging Agents.

Authors:  Takeshi Fuchigami; Takeshi Chiga; Sakura Yoshida; Makoto Oba; Yu Fukushima; Hiromi Inoue; Akari Matsuura; Akira Toriba; Morio Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.